CN112336764A - Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof Download PDFInfo
- Publication number
- CN112336764A CN112336764A CN202011222240.8A CN202011222240A CN112336764A CN 112336764 A CN112336764 A CN 112336764A CN 202011222240 A CN202011222240 A CN 202011222240A CN 112336764 A CN112336764 A CN 112336764A
- Authority
- CN
- China
- Prior art keywords
- parts
- ganoderma lucidum
- wall
- powder
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity and a preparation method and application thereof. The traditional Chinese medicine composition comprises 500-900 parts of salvia miltiorrhiza, 500-900 parts of lucid ganoderma, 100-300 parts of pseudo-ginseng, 100-200 parts of safflower and 200-500 parts of wall-broken lucid ganoderma spore powder. The composition provided by the invention is suitable for resisting oxidation, enhancing immunity and/or preventing thrombosis and/or improving cardiac function, has proper compatibility, simple and clear preparation method and obvious effect, and can effectively improve the oxidation resistance and the immunity of organisms.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity and a preparation method and application thereof.
Background
The understanding of human health concept is further deepened with the development of the scientific and technological level, and according to the research findings of more than 50 national medical experts of the world health organization, the best treatment and prevention of various diseases are realized. Any disease can be prevented and maintained first, the incidence of the disease is very low, and even the disease can be completely solved and avoided. The most important means for preventing diseases is to enhance the immunity and the oxidation resistance of the organism. Especially cardiovascular diseases with leading fatality in current society, prior art studies have learned that scavenging free radicals, reducing oxidatively damaged proteins can reduce the incidence of cardiovascular diseases.
However, in the prior art, health care medicines for cardiovascular diseases are mainly supplemented, namely various vitamins or micromolecular amino acids and the like are directly supplemented, and the health care medicines also have certain effect on human bodies after being taken, but the self resistance to the cardiovascular diseases is reduced after the health care medicines are not taken, the internal environment of visceral organs of the human bodies is not improved, and the human bodies have the resistance to the cardiovascular diseases. A small part of health care medicines designed according to the treatment idea of strengthening body resistance and eliminating pathogenic factors have diarrhea or adverse reactions such as palpitation and insufficient blood supply of patients due to improper compatibility or improper selection of medicinal materials.
Disclosure of Invention
The traditional Chinese medicine composition provided by the invention is appropriate in compatibility, and can effectively improve the oxidation resistance and enhance the resistance of cardiovascular and cerebrovascular diseases.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity, which is characterized by comprising the following raw materials in parts by weight: 500-900 parts of salvia miltiorrhiza, 500-900 parts of ganoderma lucidum, 100-300 parts of pseudo-ginseng, 100-200 parts of safflower and 200-500 parts of wall-broken ganoderma lucidum spore powder.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 640 parts of salvia miltiorrhiza, 650 parts of lucid ganoderma, 180 parts of pseudo-ginseng, 120 parts of safflower and 240 parts of wall-broken lucid ganoderma spore powder.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: pulverizing the salvia miltiorrhiza and the ganoderma lucidum in the raw materials to obtain mixed powder, decocting the mixed powder with water to obtain a medicinal decoction, sequentially concentrating and drying the medicinal decoction to obtain a dried substance, and mixing the dried substance with the pseudo-ginseng, the safflower and the wall-broken ganoderma lucidum spore powder to obtain the traditional Chinese medicine composition;
or
Pulverizing Saviae Miltiorrhizae radix and Ganoderma respectively, decocting in water, mixing to obtain decoction, concentrating and drying the decoction in sequence to obtain dried extract, and mixing the dried extract with Notoginseng radix, Carthami flos and wall-broken Ganoderma spore powder to obtain Chinese medicinal composition.
Preferably, the wall-broken ganoderma lucidum spore powder is provided in the form of a wall-broken ganoderma lucidum spore powder extract; the preparation method of the wall-broken ganoderma lucidum spore powder extract comprises the following steps: extracting the wall-broken ganoderma lucidum spore powder with water to obtain filtrate, concentrating the filtrate under reduced pressure to obtain concentrated solution, drying and sieving the concentrated solution to obtain the wall-broken ganoderma lucidum spore powder extract.
Preferably, the concentration conditions include: the concentration temperature is 60-80 ℃, and the vacuum degree of the concentration is-0.08-0.06 Mpa.
Preferably, the method of drying comprises spray drying; the conditions of the spray drying include: the air inlet temperature is 170-180 ℃, and the air outlet temperature is 90-105 ℃.
Preferably, after the salvia miltiorrhiza and the lucid ganoderma are crushed, the particle size of the obtained salvia miltiorrhiza powder or lucid ganoderma powder is 10-16 meshes; the particle diameters of the pseudo-ginseng and the safflower are independent and are 80-100 meshes.
The invention also provides application of the traditional Chinese medicine composition in the technical scheme in preparing a medicine for resisting oxidation and enhancing immunity.
The invention also provides application of the traditional Chinese medicine composition in the technical scheme in preparing a medicine for preventing thrombosis and/or in preparing a medicine for improving cardiac function.
Preferably, the dosage form of the medicament comprises tablets, powders, capsules, oral liquid, injections, sprays, aerosols, powders, mists, lotions, liniments, pastes, emulsions, patches, eye drops, nasal drops, suppositories, pills, microsphere preparations or tinctures.
The invention provides a technical scheme of a traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity. The traditional Chinese medicine composition with the functions of resisting oxidation and enhancing immunity provided by the invention takes the ganoderma lucidum and the ganoderma lucidum spore powder as monarch drugs, nourishes the five internal organs, replenishes qi and blood, nourishes the five internal organs and qi and blood, and achieves good effects of resisting oxidation and delaying senescence. The pseudo-ginseng is a ministerial drug and mainly plays a role in promoting blood circulation and removing blood stasis; the salvia miltiorrhiza is an adjuvant drug and can activate blood and remove stasis, dredge meridians and relieve pain, clear heart and relieve restlessness; the combination of the two medicines can eliminate blood stasis of qi and blood systems without damaging qi and blood of the organism. Safflower is a guiding drug, has pungent and warm properties, enters heart and liver channels, has the effects of activating blood and stimulating menstrual flow, removing blood stasis and relieving pain, can introduce the drug effect of the whole formula to the blood vessels of the whole body, and can effectively play the role of oxidation resistance. The results of the examples show that the traditional Chinese medicine preparation provided by the invention can provide an antioxidant effect, and also can improve the cardiac function and prevent the formation of thrombus.
Drawings
FIG. 1 is a staining chart of red blood cells of zebra fish heart after treatment in example 4 provided by the invention;
FIG. 2 is a graph showing the effect of example 4 on heart enlargement and venous congestion of heart failure zebra fish according to the present invention;
FIG. 3 shows zebra of blank control group and experimental group of Chinese medicinal compositionComparing the relative fluorescence value (pixel) of fish with that of a normal control group, wherein 1-8 groups are arranged from left to right,#p<0.05，##p<0.01，###p<0.001；
FIG. 4 is a comparison of zebrafish ROS scavenging action (%) of blank control group and Chinese medicinal composition experimental group with that of normal control group, wherein 2-8 groups are sequentially arranged from left to right,#p<0.05，##p<0.01，###p<0.001。
Detailed Description
The invention provides a traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity, which comprises the following raw materials in parts by weight: 500-900 parts of salvia miltiorrhiza, 500-900 parts of ganoderma lucidum, 100-300 parts of pseudo-ginseng, 100-200 parts of safflower and 200-500 parts of wall-broken ganoderma lucidum spore powder.
The traditional Chinese medicine composition provided by the invention at least contains 0.95g of salvianolic acid, 9.46g of crude polysaccharide and 3.53g of total saponins in each 100g of the traditional Chinese medicine composition.
The traditional Chinese medicine composition comprises 500-900 parts by weight of salvia miltiorrhiza; preferably 640 parts of salvia miltiorrhiza. The source of the salvia miltiorrhiza is not particularly limited in the invention, and conventional commercial products of the salvia miltiorrhiza which are well known to those skilled in the art can be adopted. The salvia miltiorrhiza has the effects of promoting blood circulation to regulate menstruation, removing blood stasis to relieve pain, cooling blood to cure carbuncle, clearing away the heart-fire to relieve restlessness, nourishing blood and soothing nerves.
The traditional Chinese medicine composition provided by the invention also comprises 500-900 parts of lucid ganoderma by weight based on the parts by weight of the salvia miltiorrhiza; preferably 650 parts. The source of the ganoderma lucidum is not particularly limited in the invention, and conventional commercial products of ganoderma lucidum well known to those skilled in the art can be adopted. The lucid ganoderma is sweet in taste and mild in nature. It enters heart, lung, liver and kidney meridians. Ganoderma can be used for treating consumptive disease, cough, asthma, insomnia, and dyspepsia.
The traditional Chinese medicine composition provided by the invention also comprises 100-300 parts of pseudo-ginseng by weight based on the parts by weight of the salvia miltiorrhiza; preferably 180 parts. The source of the notoginseng is not particularly limited in the present invention, and conventional commercial products of notoginseng known to those skilled in the art can be used. The pseudo-ginseng of the invention is sweet and slightly bitter in taste and warm in nature, enters liver and stomach channels, is used as a medicine by roots and rhizomes, is a rare Chinese medicinal material, and can stop bleeding, remove blood stasis, reduce swelling and relieve pain when being used unprocessed.
The traditional Chinese medicine composition provided by the invention also comprises 100-200 parts of safflower by weight based on the parts of the salvia miltiorrhiza; preferably 120 parts. The source of the safflower is not particularly limited in the present invention, and conventional commercially available products of safflower known to those skilled in the art can be used. The safflower of the invention has the functions of activating blood and stimulating the menstrual flow, dissipating blood stasis and relieving pain, and is used for amenorrhea, dysmenorrhea, lochiorrhea, abdominal mass, traumatic injury and sore and ulcer swelling and pain.
Based on the weight parts of the salvia miltiorrhiza, the traditional Chinese medicine composition provided by the invention also comprises 200-500 parts of wall-broken ganoderma lucidum spore powder; preferably 240 parts. The source of the wall-broken ganoderma lucidum spore powder is not specially limited, and the conventional commercial product of the wall-broken ganoderma lucidum spore powder known by the technical personnel in the field can be adopted.
Under the guidance of the theory of traditional Chinese medicine, the traditional Chinese medicine composition takes the ganoderma lucidum and the ganoderma lucidum spore powder as monarch drugs, nourishes the five internal organs, replenishes qi and blood, nourishes the five internal organs and qi and blood, and achieves the effects of resisting oxidation and delaying senility; the pseudo-ginseng is a ministerial drug and mainly plays a role in promoting blood circulation and removing blood stasis; the salvia miltiorrhiza is an adjuvant drug and can activate blood and remove stasis, dredge meridians and relieve pain, clear heart and relieve restlessness; the salvia miltiorrhiza can nourish blood and activate blood, and the panax notoginseng can activate blood and remove stasis, so that the blood of qi and blood stagnation can be eliminated without damaging qi and blood of the organism; safflower is a guiding drug, has pungent and warm properties, enters heart and liver channels, has the effects of activating blood and stimulating menstrual flow, removing blood stasis and relieving pain, can introduce the drug effect of the whole formula to the blood vessels of the whole body, and can effectively play the role of oxidation resistance. The traditional Chinese medicine composition provided by the invention has the effects of removing blood stasis and not damaging healthy energy for people with blood stasis and restlessness.
The invention provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
pulverizing the salvia miltiorrhiza and the ganoderma lucidum in the raw materials to obtain mixed powder, decocting the mixed powder with water to obtain a medicinal decoction, sequentially concentrating and drying the medicinal decoction to obtain a dried substance, and mixing the dried substance with the pseudo-ginseng, the safflower and the wall-broken ganoderma lucidum spore powder to obtain the traditional Chinese medicine composition.
In the invention, the number of times of decoction is preferably three, and the amount of water used in each decoction is preferably 1: 8-15, and the time for each decoction is preferably 50-70 min.
After the medicine decoction is obtained, the medicine decoction is sequentially concentrated and dried to obtain a dried substance.
In the present invention, the conditions for the concentration are preferably: the temperature is 60-80 ℃, and the vacuum degree is-0.08 to-0.06 Mpa.
In the present invention, the method of drying is preferably spray drying; the conditions of spray drying are preferably that the air inlet temperature is 170-180 ℃ and the air outlet temperature is 90-105 ℃; further preferably, the air inlet temperature is 180 ℃ and the air outlet temperature is 100 ℃.
After the dry matter is obtained, the dry matter is mixed with pseudo-ginseng, safflower and wall-broken ganoderma lucidum spore powder to obtain the traditional Chinese medicine composition.
In the invention, the salvia miltiorrhiza and the lucid ganoderma are crushed to be 10-16 meshes in particle size; pulverizing the pseudo-ginseng and the safflower until the particle size is preferably 80-100 meshes; the particle size of the wall-broken ganoderma lucidum spore powder extract is preferably 80-100 meshes.
In the present invention, the wall-broken ganoderma lucidum spore powder is preferably provided in the form of a wall-broken ganoderma lucidum spore powder extract; the preparation method of the extract of the wall-broken ganoderma lucidum spore powder preferably comprises the following steps: extracting the wall-broken ganoderma lucidum spore powder with water to obtain filtrate, combining the filtrates, concentrating under reduced pressure to obtain concentrated solution, drying and sieving the concentrated solution to obtain the wall-broken ganoderma lucidum spore powder extract. In the invention, the number of water extractions is preferably 3, the time of each water extraction is preferably 2 hours, and the mass ratio of the wall-broken ganoderma lucidum spore powder to the water is preferably 1: 10-15, 1: 9 to 10 and 1: 9 to 10. The preferable conditions for concentrating the filtrate under reduced pressure are vacuum degree of-0.07 MPa and temperature of 60-70 ℃. The drying temperature of the concentrated solution is preferably 60-70 ℃, the vacuum degree is preferably-0.08 MPa, and the sieving mesh number is preferably 80 meshes.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
pulverizing Saviae Miltiorrhizae radix and Ganoderma, respectively decocting in water, mixing to obtain decoction, sequentially concentrating and drying to obtain dried extract, and mixing with Notoginseng radix and Carthami flos to obtain Chinese medicinal composition.
The invention is characterized in that salvia miltiorrhiza and lucid ganoderma in the raw materials are respectively decocted in water after being crushed, and the decoction is obtained after being combined.
In another method for preparing the traditional Chinese medicine composition, the requirements of the crushed particle sizes of the salvia miltiorrhiza and the lucid ganoderma are the same as above, and the detailed description is omitted; the requirement of the pulverized particle size of the pseudo-ginseng and the safflower is the same as above, and the description is omitted.
In the present invention, the number of times of the water decoction is preferably two; when the salvia miltiorrhiza is decocted, the mass ratio of the salvia miltiorrhiza powder to water is preferably 1: 10-16 and 1: 7-13; the time for each decoction is 20-40 min; when the ganoderma lucidum is decocted, the mass ratio of ganoderma lucidum powder to water is 1: 8-12; the time for each decoction is 110-130 min.
In another method for preparing the traditional Chinese medicine composition, the preparation method of the extract of the wall-broken ganoderma lucidum spore powder is the same as the above, and is not described again.
In another method for preparing the Chinese medicinal composition of the present invention, the concentration and drying conditions are the same as above, and are not described herein again.
The traditional Chinese medicine composition provided by the invention is convenient to store and transport, the problem that traditional medicine raw materials are not easy to store and are easy to damage by worms is solved, and the technical problem that the storage life of liquid or paste semi-finished medicine is limited is also solved.
The invention provides application of the traditional Chinese medicine composition in the technical scheme in preparing a medicine for resisting oxidation and enhancing immunity.
The invention also provides application of the traditional Chinese medicine composition in the technical scheme in preparing a medicine for preventing thrombosis and/or in preparing a medicine for improving cardiac function.
In the invention, the dosage form of the medicine comprises tablets, powder, capsules, oral liquid, injection, spray, aerosol, powder spray, lotion, liniment, ointment, emulsion, patch, eye drops, nasal drops, suppositories, pills, microsphere preparations or tinctures.
In the present invention, when the dosage form of the drug is a tablet, the preparation method of the tablet preferably includes: uniformly mixing the pharmaceutical composition with an aqueous solution of lactose, mannitol and povidone K30, and granulating to obtain granules; mixing the obtained granule with magnesium stearate, and tabletting with high speed tabletting machine to obtain tablet. The mass ratio of the traditional Chinese medicine composition to the aqueous solution of lactose, mannitol, povidone K30 and magnesium stearate in the tablet is preferably 1700: 50: 45: 40: 10. the administration method of the tablet is preferably 2 times daily, 4 tablets each time; the tablet preferably contains 0.75g of salvianolic acid B, 7.5g of crude polysaccharide and 2.8g of total saponins in every 100g of the tablet.
For further illustration of the present invention, the following detailed description of the present invention will be made with reference to the accompanying drawings and examples to provide a Chinese medicinal composition for resisting oxidation and enhancing immunity, and its preparation method and application, which should not be construed as limiting the scope of the present invention.
The amounts mentioned in the following examples are parts by weight unless otherwise specified.
Example 1
1. Weighing a plurality of salvia miltiorrhiza, crushing, sieving with a 16-mesh sieve, adding water, decocting for 2 times, wherein each time of decoction is 0.5h, and the mass of the medicinal materials and the weight of the added water are independently 1: 13 and 1:10, mixing to obtain the salvia miltiorrhiza extract. Concentrating under reduced pressure at 60 deg.C under-0.08 Mpa to obtain Saviae Miltiorrhizae radix concentrated solution. Spray drying the Saviae Miltiorrhizae radix concentrated solution at air inlet temperature of 180 deg.C and air outlet temperature of 100 deg.C, and sieving with 60 mesh sieve to obtain Saviae Miltiorrhizae radix spray dried powder.
2. Weighing a plurality of lucid ganoderma, crushing, sieving with a 10-mesh sieve, adding water, decocting for 2 times, wherein each time of decoction is 2 hours, and the mass of the medicinal materials and the weight of the added water are respectively 1:10, obtaining the ganoderma lucidum extracting solution. Concentrating under reduced pressure at 80 deg.C under vacuum degree of-0.06 MPa to obtain Ganoderma concentrated solution. Spray drying Ganoderma concentrated solution at air inlet temperature of 175 deg.C and air outlet temperature of 90 deg.C, and sieving with 60 mesh sieve to obtain Ganoderma spray dried powder.
3. Weighing a plurality of pseudo-ginseng, crushing, and sieving with a 80-mesh sieve to obtain pseudo-ginseng powder.
4. Pulverizing Carthami flos, and sieving with 100 mesh sieve to obtain Carthami flos powder.
5. Weighing a plurality of wall-broken ganoderma lucidum spore powders, putting the wall-broken ganoderma lucidum spore powders into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the medicinal material quality and the added water weight are independently 1: 10. 1: 9 and 1: 9. the vacuum degree is-0.07 MPa. Concentrating under reduced pressure at 60 deg.C to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 60 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract, i.e. Ganoderma spore powder spray-dried powder.
Example 2
1. Weighing 800 parts of salvia miltiorrhiza, crushing, sieving with a 10-mesh sieve, adding water, decocting for 2 times, each time for 0.5h, wherein the water adding amount is 1:10 and 1: 13, filtering to obtain the salvia miltiorrhiza extract.
2. Weighing 900 parts of lucid ganoderma, crushing, sieving by a 16-mesh sieve, adding water, decocting for 2 times, each time for 2 hours, and filtering by adding water in a ratio of 1:12 and a ratio of 1:8 in sequence to obtain lucid ganoderma extract.
3. Weighing 300 parts of pseudo-ginseng, crushing, and sieving with a 100-mesh sieve to obtain pseudo-ginseng powder.
4. Weighing 100 parts of safflower. Pulverizing, and sieving with 80 mesh sieve to obtain safflower powder.
5. Weighing 200 parts of wall-broken ganoderma lucidum spore powder, putting the wall-broken ganoderma lucidum spore powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of medicinal materials and the weight of added water are respectively 1: 14. 1:10 and 1: 10. vacuum concentrating at-0.07 MPa and 65 deg.C to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 65 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract.
And (3) combining the extracting solutions obtained in the steps (1) and (2), and concentrating under reduced pressure at the vacuum degree of-0.08 MPa and the temperature of 70 ℃ to obtain a medicinal material concentrated solution. Spray drying the concentrated solution at air inlet temperature of 170 deg.C and air outlet temperature of 105 deg.C, and sieving with 60 mesh sieve to obtain medicinal spray powder. And (3) uniformly mixing the medicinal spray-dried powder with the pseudo-ginseng powder, the safflower powder and the ganoderma lucidum spore powder extracts obtained in the steps (3), (4) and (5) to obtain the traditional Chinese medicine composition.
Example 3
1. Weighing 700 parts of salvia miltiorrhiza, crushing, sieving by a 14-mesh sieve, adding water, decocting for 2 times, each time for 0.5h, wherein the water adding amount is 1: 16 and 1:7, filtering to obtain the salvia miltiorrhiza extract.
2. Weighing 650 parts of lucid ganoderma, crushing, sieving by a 12-mesh sieve, adding water, decocting for 2 times, each time for 2 hours, and filtering by adding water in a ratio of 1:8 and 1:12 in sequence to obtain lucid ganoderma extract.
3. Weighing 250 parts of pseudo-ginseng, crushing, and sieving with a 100-mesh sieve to obtain pseudo-ginseng powder.
4. 200 parts of safflower is weighed. Pulverizing, and sieving with 100 mesh sieve to obtain safflower powder.
5. Weighing 220 parts of wall-broken ganoderma lucidum spore powder, putting the wall-broken ganoderma lucidum spore powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of the medicinal materials and the weight of added water are respectively 1: 12. 1:10 and 1: 10. vacuum concentrating at 70 deg.C under vacuum degree of-0.07 MPa to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 70 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract.
And (3) combining the extracting solutions in the steps (1) and (2), and concentrating under reduced pressure at the vacuum degree of-0.07 MPa and the temperature of 60 ℃ to obtain a medicinal material concentrated solution. Spray drying the concentrated solution at air inlet temperature of 170 deg.C and air outlet temperature of 105 deg.C, and sieving with 60 mesh sieve to obtain medicinal spray powder. And (3) uniformly mixing the medicinal spray-dried powder with the pseudo-ginseng powder, the safflower powder and the ganoderma lucidum spore powder extracts obtained in the steps (3), (4) and (5) to obtain the traditional Chinese medicine composition.
Example 4
Weighing 640 parts of salvia miltiorrhiza and 650 parts of lucid ganoderma, crushing, sieving by a 16-mesh sieve, and mixing. Decocting in water for 3 times, each time for 1h, wherein the mass ratio of the total mass of the traditional Chinese medicine raw materials to water is 1:15, 1:10 and 1:8 respectively, to obtain medicine extract. Concentrating the obtained medicinal extractive solution under reduced pressure at vacuum degree of-0.07 Mpa and temperature of 60 deg.C to obtain medicinal concentrated solution. Spray drying the concentrated solution at air inlet temperature of 180 deg.C and air outlet temperature of 100 deg.C, sieving with 60 mesh sieve, and grading to obtain medicinal spray dried powder. Weighing 240 parts of wall-broken ganoderma lucidum spore powder, putting the powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of the medicinal materials and the weight of added water are respectively 1: 12. 1:10 and 1: 10. vacuum concentrating at 70 deg.C under vacuum degree of-0.07 MPa to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 70 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract. Weighing 180 parts of pseudo-ginseng powder and 120 parts of safflower powder, and mixing with the medicinal spray-dried powder to obtain the traditional Chinese medicine composition.
Application example 1
Experimental animals: ICR mice, after adaptive culture, were randomly divided into 9 groups of 10 mice each. The test group is divided into a blank group, a model control group and 7 drug test groups.
Blank group, normal culture, no treatment, and no fasting material. The model control group was gavaged with distilled water of the same volume as the experimental group once a day for 30 consecutive days, and fasted for 16 hours (overnight) after the last gavage, and then subjected to one-time gavage with 50% ethanol 12mL/kgBW, and the materials were taken after 6 hours. The medicines fed by the experimental group of medicines are the pseudo-ginseng powder, the red-rooted salvia root spray-dried powder, the safflower powder, the lucid ganoderma spray-dried powder, the traditional Chinese medicine composition provided by the embodiment 1, the traditional Chinese medicine composition provided by the embodiment 3 and the traditional Chinese medicine composition provided by the embodiment 4 respectively. The drug solutions are respectively prepared into 0.30g/mL, and the drug solutions are fed to model mice in a gavage mode at a dose of 0.1g/10g once a day for 30 consecutive days. After the last gastric lavage, the material was taken from the same model control group.
Material taking operation: liver tissue of the mouse is taken, frozen by liquid nitrogen and stored in the environment of minus 40 ℃. The activity of superoxide dismutase (SOD), the content of reduced Glutathione (GSH), Malondialdehyde (MDA) and protein carbonyl are determined by using a kit of Nanjing institute of bioengineering. The BCA method protein concentration measurement kit is provided by Biotechnology (Shanghai) Co., Ltd.
The results of testing the liver tissue MDA content, SOD activity, GSH content and protein carbonyl content of the mouse with the ethanol oxidation damage model are shown in Table 1.
TABLE 1 test substance for mouse liver tissue SOD activity,Effect of MDA, GSH and protein carbonyl content
Compared with a blank control group, the liver tissue SOD activity and the GSH content of the mouse of the model control group are both reduced, the MDA content and the protein carbonyl content are both increased, and the difference is significant (t test, P is less than 0.05). The model is established.
The drug effect of each drug in the traditional Chinese medicine composition used in the invention when being used as a single component and the drug effect of the traditional Chinese medicine composition provided in examples 2-4 are verified through drug tests, and specific results are shown in table 2.
TABLE 2 Effect of test substances on mouse liver tissue SOD Activity, MDA, GSH and protein carbonyl content
As can be seen from Table 2, the 7 drugs provided in example 1 all have the effects of reducing MDA content and protein carbonyl content, increasing SOD activity and GSH content, and thus show that the 7 drugs all have different degrees of antioxidant activity. However, the antioxidant activity of the pharmaceutical compositions provided in examples 2, 3 and 4 is higher than that of a single medicinal material. The pharmaceutical composition provided by the invention has a remarkable synergistic effect in the aspect of body antioxidation.
Application example 2
The pseudo-ginseng powder, the spray dried powder of red sage root, the safflower powder, the spray dried powder of ganoderma lucidum, the Chinese medicinal composition provided in example 2, the Chinese medicinal composition provided in example 3 and the Chinese medicinal composition provided in example 4 were prepared into 0.30g/mL of medicinal solutions, respectively, as test substances.
Model animals: female ICR mice, 10 mice per experimental group were randomly grouped.
The administration mode comprises the following steps: and (5) performing intragastric administration.
The dosage is as follows: 0.1g/10g of weight meter.
The test method comprises the following steps:
1. ConA-induced splenic lymphocyte transformation assay in mice: each group of 10 mice were gavaged once a day for 29 consecutive days. On the 30 th day of the experiment, the spleen was removed, shredded with forceps to form a single cell suspension, filtered through a 200-mesh screen, washed, counted and finally adjusted to a cell concentration of 3X 10 using RPMI1640 complete medium6one/mL. The cell suspension was added to a 24-well plate in two wells, 1mL per well, 75. mu.L ConA solution (equivalent to 7.5. mu.g/mL) per well, and the other well was used as a control and incubated at 37 ℃ with 5% CO2The culture box is used for culturing for 72 hours. 4h before the end of the culture, 0.7mL of the supernatant was gently aspirated from each well, and 0.7mL of RPMIl640 medium without calf serum was added together with 50. mu.L of MTT (5mg/mL) per well, and the culture was continued for 4 h. After the culture is finished, 1mL of acidic isopropanol is added into each hole, and the mixture is uniformly blown and beaten to ensure that the purple crystals are completely dissolved. The optical density value (0D) was determined at a wavelength of 570 nm. Finally, the optical density of the ConA-added wells minus the optical density of the non-ConA-added wells represents the proliferative capacity of lymphocytes.
2. Mouse serum hemolysin assay (hemagglutination) each group was gavaged once a day for 30 consecutive days with the test substance. On test day 25, each mouse was immunized by intraperitoneal injection of 0.2mL of a 2% (V/V) packed Sheep Red Blood Cell (SRBC) suspension. After 5 days, blood was centrifuged, serum was collected, diluted by a multiple ratio with physiological saline, incubated at 37 ℃ for 3 hours in an incubator, the degree of hemagglutination was observed, and the number of antibody products was calculated.
3. The mouse splenocyte antibody production capacity test (Jerne modified slide method) is performed on the 25 th day by gastric lavage, and each mouse is injected with 0.2mL of 2% (V/V) Sheep Red Blood Cells (SRBC) in the abdominal cavity for immunization. After 5 days, the spleen was removed, and Hank's solution was added to the spleen to prepare a single cell suspension, which was then filtered, washed, suspension counted, and the cell concentration was adjusted to 5X 106 cells/mL. Heating surface layer culture medium (0.1g/mL agarose) for dissolving, mixing with 2 times concentration Hanks solution, subpackaging, 0.5 mL/tube, maintaining temperature in 45 deg.C water bath, adding 50 μ L10% (V/V) SRBC and 20 μ L spleen cell suspension, pouring onto glass coated with thin agarose layer, solidifying, placing, and adding CO2Incubate at 37 ℃ for 1.5h, 1:8 is thinReleased complement was added to the slide rack wells and the number of lyso-plaques counted after 1.5h incubation.
4. Mouse abdominal cavity macrophage phagocytosis chicken erythrocyte test (semi-in vivo method) each group was administered the test substance by gastric gavage once a day for 32 consecutive days. 30min before the animal is killed, injecting 1mL of 20% (V/V) chicken erythrocyte suspension into abdominal cavity of each mouse, injecting 2mL of normal saline after the animal is killed, taking abdominal cavity liquid drop tablets, incubating for 30min at 37 ℃, fixing, dyeing, performing microscopic examination, counting 100 macrophages, and calculating phagocytosis rate and phagocytosis index.
The results of the above four-aspect test are shown in table 3:
TABLE 3 Effect of drugs on test substance Immunity
As can be seen from table 3, the tested 7 drugs all have different degrees of immunity enhancing functions, and the pharmaceutical compositions provided in examples 2, 3 and 4 all have better effects than the single medicinal material, which indicates that the traditional Chinese medicine composition or the pharmaceutical composition of the present invention has synergistic effect in enhancing immunity.
Application example 3
Treating the wild AB-series zebra fish for 24h by using phenylhydrazine to establish a zebra fish thrombus model. The traditional Chinese medicine composition provided in example 4 was taken.
Wild-type AB zebra fish was randomly selected in six-well plates, 30 fish per well, and the Chinese medicinal composition provided in example 4 was separately administered in water at the following concentrations: 100 mug/mL, 333 mug/mL and 1000 mug/mL, positive control drug clopidogrel with concentration of 7.5 mug/mL and 3mL solution per well, and a normal control group (without any treatment) and a model control group are arranged at the same time. After the drug is administered for 6 hours, after a zebra fish thrombus model is induced by phenylhydrazine, dyeing is carried out by using o-dianisidine, 10 zebra fish are randomly selected from each experimental group after dyeing, the zebra fish is photographed under an anatomical microscope and data is acquired (details of a staining graph of the heart red blood cells of the zebra fish are shown in figure 1, a green area is a quantitative area), image analysis is carried out by using NIS-Elements DTM image processing software, the staining intensity (S) of the heart red blood cells of the zebra fish is calculated, the length of the tail vein thrombus is inversely proportional to the number of the heart red blood cells (the staining intensity of the red blood cells), and evaluation indexes are determined according to Hangzhou special biotechnology, namely the patent number: 201110126427 ], quantitative analysis, statistical treatment results expressed as mean ± SE, and the calculation formula of the thrombus-preventing effect of example 4 is as follows:
statistical analysis was performed using analysis of variance and Dunnett's T-test, p <0.05 indicating significant differences, and specific data analysis is shown in Table 4.
Table 4 example 4 quantification of thrombus prevention after treatment (n ═ 10)
Note: p <0.01, p <0.001, compared to model controls.
As shown in Table 4, the comparison of the staining intensity of the red blood cells of the zebra fish heart (1492) in the model control group with the normal control group (3125) shows that p is less than 0.001, which indicates that the model is successfully established. Compared with a model control group (1492), the positive control drug clopidogrel zebrafish heart red blood cell staining intensity (2053) has p <0.001, the effect of preventing the zebrafish thrombosis is 34%, and the result shows that 7.5 mu g/mL clopidogrel has the effect of preventing the thrombosis.
The use of the traditional Chinese medicine composition provided in example 4 at the following concentrations of drugs: the staining intensity of the red blood cells of the tested zebra fish heart of 100 mu g/mL, 333 mu g/mL and 1000 mu g/mL is 2503, 3034 and 2029 respectively, and the thrombus prevention effect is 62%, 94% and 33% respectively, compared with a model control group, the three concentration groups p <0.01& p <0.001, which shows that the traditional Chinese medicine preparation provided by the invention has the effect of preventing the zebra fish thrombus induced by phenylhydrazine under the condition of the experimental concentration.
Application example 4
Treating wild AB line zebra fish with verapamil for 30min, and establishing a zebra fish heart failure model. The Chinese medicinal composition provided in example 4 was used as an experimental sample.
Wild type AB line zebra fish were randomly selected in six well plates with 30 tails per well. The method comprises the steps of establishing a zebra fish heart failure model by verapamil induction, and respectively carrying out water-soluble administration on the pharmaceutical composition with the concentration of 100 mug/mL, 333 mug/mL and 1000 mug/mL provided in the embodiment 4 and the positive control drug clopidogrel with the concentration of 7.5 mug/mL and the concentration of 3mL in each hole; setting a normal control group and a model control group. After the drug treatment is finished, on one hand, 10 zebra fishes are randomly selected from each group and placed under an anatomical microscope to be photographed (the magnification is 56 times, and the detailed view is shown in figure 2), and the heart enlargement area and the venous congestion area of the zebra fishes are analyzed; on the other hand, 10 zebra fish are randomly selected from each group and placed in a heartbeat and blood flow analysis system to record zebra fish blood flow videos, the cardiac output and the blood flow speed of the zebra fish are analyzed, and the heart function improvement effect of the pharmaceutical composition provided in the embodiment 4 on the verapamil-induced zebra fish heart failure is quantitatively evaluated. The improvement effect of the sample on the heart failure zebra fish is calculated as follows:
1) treating effect on pericardial edema caused by heart failure
2) Improvement of venous congestion caused by heart failure
3) Influence on cardiac output
4) Influence on blood flow velocity
Statistical analysis using analysis of variance and Dunnett's T-test, p <0.05 indicated significant differences.
The area is measured by pixels, the unit of cardiac output is mu L/s, and the unit of blood flow velocity is mm/s; comparing the heart area (10699), the venous stasis area (3544), the cardiac output (0.15) and the blood flow velocity (562) of the zebra fish in the model control group with the heart area (6803), the venous stasis area (1129), the cardiac output (0.24) and the blood flow velocity (771) of the normal control group to ensure that p is less than 0.001, which indicates that the model is successfully established.
1. The area (pixel) of the heart of the traditional Chinese medicine composition provided in example 4 is 7228, 7682 and 8921 at concentrations of 100 μ g/mL, 333 μ g/mL and 1000 μ g/mL, respectively, the heart enlargement improvement rates are 89%, 77% and 46% respectively compared with the model control group, and p is <0.01& p <0.001 compared with the model control group. The area of the heart of the positive control drug digoxin is 7746, the heart enlargement improvement rate is 76 percent, and p is less than 0.001 compared with a model control group.
2. The traditional Chinese medicine composition provided in example 4 has areas (pixels) of venous congestion of 2236, 2418 and 3189 at concentrations of 100. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL, respectively, and has venous congestion improvement rates of 54%, 47% and 15% compared with the model control group, 1000. mu.g/mL group p >0.05 compared with the model control group, and the remaining two groups p < 0.001. The area of the positive control drug digoxin venous congestion is 1934, the improvement rate of the venous congestion is 67%, and p is less than 0.001 compared with a model control group.
3. The Chinese medicinal composition provided in example 4 has cardiac output (μ L/s) of 0.20, 0.19 and 0.15 at concentrations of 100 μ g/mL, 333 μ g/mL and 1000 μ g/mL, respectively, and the rate of increase in cardiac output is 49%, 40% and 1%, respectively, compared with the model control group, p is >0.05 in the 1000 μ g/mL group, and p is <0.05& p <0.01 in the remaining two groups. The positive control drug digoxin has cardiac output of 0.21 and cardiac output increase rate of 67%, and p is less than 0.001 compared with the model control group.
4. The Chinese medicinal composition provided in example 4 has blood flow rates (mm/s) of 705, 662 and 530 at concentrations of 100. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL, respectively, and blood flow rate increases of 68%, 48% and-15%, respectively, with p >0.05 in the 1000. mu.g/mL group and p <0.05& p <0.001 in the remaining two groups, compared with the model control group. The positive control drug digoxin has a blood flow rate (mm/s) of 672% and a blood flow rate increase of 53%, and p is less than 0.01 compared with the model control group. The specific test data are shown in tables 5, 6, 7 and 8.
Table 5 the effect of the Chinese medicinal composition provided in example 4 on the improvement of heart failure zebra fish heart enlargement (n ═ 10)
Note: p <0.01 × p <0.001 compared to model control group.
Table 6 the effect of the Chinese medicinal composition provided in example 4 on improving venous stasis of heart failure zebra fish (n ═ 10)
Note: p <0.001 compared to model control group.
Table 7 effect of the chinese medicinal composition provided in example 4 on improving cardiac output of heart failure zebra fish (n ═ 10)
Note: p <0.05, p <0.01, p <0.001, compared to model controls.
Table 8 effect of the chinese medicinal composition provided in example 4 on improving blood flow rate of heart failure zebra fish (n ═ 10)
Note: p <0.05, p <0.001 compared to model controls.
Application example 5
(1) Weighing 800 parts of salvia miltiorrhiza, crushing, sieving with a 10-mesh sieve, adding water, decocting for 2 times, each time for 0.5h, wherein the water adding amount is 1:10 and 1: 13, filtering to obtain the salvia miltiorrhiza extract.
(2) Weighing 900 parts of lucid ganoderma, crushing, sieving by a 16-mesh sieve, adding water, decocting for 2 times, each time for 2 hours, and filtering by adding water in a ratio of 1:12 and a ratio of 1:8 in sequence to obtain lucid ganoderma extract.
(3) Weighing 300 parts of pseudo-ginseng, crushing, and sieving with a 100-mesh sieve to obtain pseudo-ginseng powder.
(4) Weighing 100 parts of safflower. Pulverizing, and sieving with 80 mesh sieve to obtain safflower powder.
(5) Weighing 200 parts of wall-broken ganoderma lucidum spore powder, putting the wall-broken ganoderma lucidum spore powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of medicinal materials and the weight of added water are independently 1: 14. 1:10 and 1: 10. the vacuum degree is-0.07 MPa. Concentrating under reduced pressure at 65 deg.C to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 65 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract.
And (3) combining the extracting solutions obtained in the steps (1) and (2), and concentrating under reduced pressure at the vacuum degree of-0.08 MPa and the temperature of 70 ℃ to obtain a medicinal material concentrated solution. Spray drying the concentrated solution at air inlet temperature of 170 deg.C and air outlet temperature of 105 deg.C, and sieving with 60 mesh sieve to obtain medicinal spray powder. And (4) uniformly mixing the medicinal spray-dried powder with the pseudo-ginseng powder, the safflower powder and the wall-broken ganoderma lucidum spore powder extracts obtained in the steps (3), (4) and (5) to obtain the medicinal composition.
Adding 50 parts of lactose and 45 parts of mannitol into the pharmaceutical composition, and performing one-step granulation by taking the aqueous solution of povidone K30 as a binder to obtain the granular product of the invention.
Application example 6
(1) Weighing 800 parts of salvia miltiorrhiza, crushing, sieving with a 10-mesh sieve, adding water, decocting for 2 times, each time for 0.5h, wherein the water adding amount is 1:10 and 1: 13, filtering to obtain the salvia miltiorrhiza extract.
(2) Weighing 900 parts of lucid ganoderma, crushing, sieving by a 16-mesh sieve, adding water, decocting for 2 times, each time for 2 hours, and filtering by adding water in a ratio of 1:12 and a ratio of 1:8 in sequence to obtain lucid ganoderma extract.
(3) Weighing 300 parts of pseudo-ginseng, crushing, and sieving with a 100-mesh sieve to obtain pseudo-ginseng powder.
(4) Weighing 100 parts of safflower. Pulverizing, and sieving with 80 mesh sieve to obtain safflower powder.
(5) Weighing 200 parts of wall-broken ganoderma lucidum spore powder, putting the wall-broken ganoderma lucidum spore powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of medicinal materials and the weight of added water are independently 1: 14. 1:10 and 1: 10. the vacuum degree is-0.07 MPa. Concentrating under reduced pressure at 65 deg.C to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 65 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract.
And (3) combining the extracting solutions obtained in the steps (1) and (2), and concentrating under reduced pressure at the vacuum degree of-0.08 MPa and the temperature of 70 ℃ to obtain a medicinal material concentrated solution. Spray drying the concentrated solution at air inlet temperature of 170 deg.C and air outlet temperature of 105 deg.C, and sieving with 60 mesh sieve to obtain medicinal spray powder. And (4) uniformly mixing the medicinal spray-dried powder with the pseudo-ginseng powder, the safflower powder and the wall-broken ganoderma lucidum spore powder extracts obtained in the steps (3), (4) and (5) to obtain the medicinal composition.
Adding lactose and mannitol into the traditional Chinese medicine composition, and performing one-step granulation by taking the water solution of povidone K30 as a binder to obtain the granular product of the invention. Adding magnesium stearate into the obtained granule product, wherein the mass ratio of the traditional Chinese medicine composition in the tablet to the aqueous solution of lactose, mannitol, povidone K30 and magnesium stearate is 1700: 50: 45: 40: 10. after the total mixing, the tablets are compressed by a high-speed tablet press to obtain the tablet product of the invention.
Application example 7
Weighing 750 parts of salvia miltiorrhiza and 800 parts of lucid ganoderma, crushing, sieving by a 16-mesh sieve, and mixing. Decocting in water for 3 times, each time for 1h, wherein the mass ratio of the total mass of the traditional Chinese medicine raw materials to water is 1:15, 1:10 and 1:8 respectively, to obtain medicine extract. Concentrating the obtained medicinal extractive solution under reduced pressure at vacuum degree of-0.07 Mpa and temperature of 60 deg.C to obtain medicinal concentrated solution. Spray drying the concentrated solution at air inlet temperature of 180 deg.C and air outlet temperature of 100 deg.C, sieving with 60 mesh sieve, and grading to obtain medicinal spray dried powder. Weighing 270 parts of wall-broken ganoderma lucidum spore powder, putting the wall-broken ganoderma lucidum spore powder into an extraction tank, carrying out water extraction for 3 times, wherein the extraction time is 2 hours each time, and the mass of medicinal materials and the weight of added water are independently 1: 12. 1:10 and 1: 10. the vacuum degree is-0.07 MPa. Concentrating under reduced pressure at 70 deg.C to obtain wall-broken Ganoderma spore powder concentrated solution. Drying the concentrated solution at 70 deg.C under-0.08 MPa, and sieving with 80 mesh sieve to obtain wall-broken Ganoderma spore powder extract. Weighing 250 parts of pseudo-ginseng powder and 125 parts of safflower powder, and mixing with the medicinal spray-dried powder to obtain the traditional Chinese medicine composition.
According to the ratio of the medicinal composition to the auxiliary materials of 100: 1, and encapsulating to obtain the capsule product of the invention.
The granules, tablets and capsules provided by application examples 5-7 of the invention have the technical effects of preventing thrombus and improving heart.
Application example 8
The wild AB strain zebra fish of which tail age is 3 days (3dpf) after fertilization is taken and used for evaluating the antioxidation of the traditional Chinese medicine composition provided by the embodiment, and the wild AB strain zebra fish is obtained by breeding in a natural paired mating breeding mode.
The blank control group is tablets only containing auxiliary materials (the auxiliary materials are D-mannitol preferably 45 parts, polyvinylpyrrolidone K3040 parts, magnesium stearate 7 parts and gastric soluble film coating premix 25 parts), and has no components of the traditional Chinese medicine composition.
Grouping condition:
group 1 was a normal control group;
group 2 was a positive control group and 100. mu.M glutathione was administered;
3 groups are blank control groups, and the set concentration is 0.5 mug/mL;
4 groups are blank control groups, and the set concentration is 1.4 mug/mL;
5 groups are blank control groups, and the set concentration is 4.3 mug/mL;
group 6 was an experimental group, to which the Chinese medicinal composition provided in example 4 was administered at 2.2 μ g/mL;
group 7 is an experimental group, and 6.7 μ g/mL of the Chinese medicinal composition provided in example 4 is administered;
the 8 groups were experimental groups and the Chinese medicinal composition provided in example 4 was administered at 20. mu.g/mL.
Randomly selecting 3dpf wild type AB strain zebra fish in a 24-well plate, arranging 10 fish in each well (namely each experimental group), and arranging another parallel experiment which is respectively named as a first parallel experiment and a second parallel experiment.
The concentration of the traditional Chinese medicine composition provided in the embodiment 4 is respectively given to 6-8 groups, and the concentration of the traditional Chinese medicine composition provided in the embodiment 4 is respectively given to 3-5 groups. And adding an ROS detection reagent CM in the first parallel experiment, not adding a detection reagent in the second parallel experiment, transferring each experimental group into a 96-well plate, wherein the number of the experimental groups is 1/well, the feeding amount is 100 mu L/well, and arranging a normal control group (namely E3 treated normal zebra fish) and a substrate control group (E3 solution without zebra fish). After being treated in an incubator at 28 ℃ for a period of time, the fluorescence quantitative analysis is carried out on each group by using a multifunctional microplate reader, the fluorescence value of CM of one group of parallel experiments is subtracted by the fluorescence value of E3 of the corresponding group of parallel experiments, and then the fluorescence value of a substrate control group is subtracted to obtain the relative fluorescence value (F) of each experiment group. And evaluating the antioxidation of the traditional Chinese medicine composition and a blank control group on the zebra fish according to the statistical analysis result of the relative fluorescence value of the zebra fish. The formula for calculating the ROS eliminating effect of the traditional Chinese medicine composition and the blank control group on the zebra fish is as follows:
statistical analysis of the relative fluorescence values and ROS clearance calculated above using analysis of variance and Dunnett's T-test indicated significant differences with p < 0.05. The results are shown in table 9, fig. 3 and fig. 4.
Table 9 summary of evaluation data (relative fluorescence value) of antioxidant activity of zebra fish of each experimental group (n ═ 6)
Note: # p <0.05, # p <0.01, # p < 0.001.
As can be seen from fig. 3, fig. 4 and table 9, when the relative fluorescence value of zebra fish in the positive control group is 121 pixels compared with that of the normal control group 1713 pixels, p is less than 0.05, and the ROS scavenging effect is 92.9%, indicating that glutathione has a significant antioxidant effect on zebra fish.
The relative fluorescence values of the 3-5 groups are 1533 pixels, 1502 pixels and 1441 pixels respectively, the ROS scavenging action is 10.5%, 12.3% and 15.9% respectively, and p is more than 0.05 compared with a normal control group; the relative fluorescence values of the 6-8 groups were 1423, 572 and 15 pixels, respectively, with ROS scavenging of 16.9%, 66.6% and 99.1%, respectively, with p >0.05& p <0.01& p <0.001 compared to the normal control group. The traditional Chinese medicine composition has obvious antioxidation on the zebra fish, and the blank control group has no antioxidation on the zebra fish.
Application example 9
1. Criteria for selecting cases
1.1 inclusion criteria
Selecting the crowd who is 45-65 years old, has good physical health condition, has no obvious diseases of brain, heart, liver, lung, kidney and blood, has no long-term medicine taking history and is matched with the volunteers and the testees.
1.2 exclusion criteria
1.2.1 pregnant or lactating women, allergic to health food.
1.2.2 patients with serious diseases of heart, liver, kidney and hematopoietic system.
1.2.3 taking the article related to the tested function in a short time affects the judger of the result.
1.2.4 does not meet the inclusion standard, and if the test sample is not eaten according to the regulation, the efficacy or the data are not completely influenced or the safety is judged.
2. Treatment regimens
The treatment group used the drug prepared in example 4, 2 times daily, 4 tablets each time;
the comparative example is a placebo group, and patients received placebo 2 times a day, 4 tablets each time;
the treatment period is 3 months.
3. Criteria for efficacy assessment
Lipid peroxide content, superoxide dismutase and glutathione peroxidase content. And (3) judging that the test sample has the function of antioxidation if any one of the three tests is positive.
4. Therapeutic effects
Study subjects: the study subjects were enrolled into 200 patients in total, all from the group of volunteer subjects who were guaranteed to be matched, 100 patients in the treatment group, and 100 patients in the control group. Wherein 50 men and 50 women in the treatment group are 55 + -10 years old; in the control group, 50 men and 50 women were aged 55. + -.10 years.
After three months of treatment, the study subjects detected the content of lipid peroxide, superoxide dismutase and glutathione peroxidase respectively. After treatment, the content of lipid peroxide in a patient is reduced, the content of superoxide dismutase is increased, and the content of glutathione peroxidase is increased.
The experiments show that the traditional Chinese medicine composition provided by the invention can greatly improve the immunity of the organism and is also beneficial to improving the antioxidant capacity; can improve heart function and prevent thrombosis.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A traditional Chinese medicine composition with functions of resisting oxidation and enhancing immunity is characterized by comprising the following raw materials in parts by weight: 500-900 parts of salvia miltiorrhiza, 500-900 parts of ganoderma lucidum, 100-300 parts of pseudo-ginseng, 100-200 parts of safflower and 200-500 parts of wall-broken ganoderma lucidum spore powder.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 640 parts of salvia miltiorrhiza, 650 parts of lucid ganoderma, 180 parts of pseudo-ginseng, 120 parts of safflower and 240 parts of wall-broken lucid ganoderma spore powder.
3. A method for preparing the Chinese medicinal composition of claim 1 or 2, comprising the steps of:
pulverizing the salvia miltiorrhiza and the ganoderma lucidum in the raw materials to obtain mixed powder, decocting the mixed powder with water to obtain a medicinal decoction, sequentially concentrating and drying the medicinal decoction to obtain a dried substance, and mixing the dried substance with the pseudo-ginseng, the safflower and the wall-broken ganoderma lucidum spore powder to obtain the traditional Chinese medicine composition;
or
Pulverizing Saviae Miltiorrhizae radix and Ganoderma respectively, decocting in water, mixing to obtain decoction, concentrating and drying the decoction in sequence to obtain dried extract, and mixing the dried extract with Notoginseng radix, Carthami flos and wall-broken Ganoderma spore powder to obtain Chinese medicinal composition.
4. The method according to claim 3, wherein the wall-broken Ganoderma lucidum spore powder is provided in the form of an extract of the wall-broken Ganoderma lucidum spore powder; the preparation method of the extract of the wall-broken ganoderma lucidum spore powder comprises the following steps: extracting the wall-broken ganoderma lucidum spore powder with water to obtain filtrate, concentrating the filtrate under reduced pressure to obtain concentrated solution, drying and sieving the concentrated solution to obtain the wall-broken ganoderma lucidum spore powder extract.
5. The method of claim 3, wherein the concentrating conditions comprise: the concentration temperature is 60-80 ℃, and the vacuum degree of the concentration is-0.08-0.06 Mpa.
6. The method of claim 3, wherein the drying method comprises spray drying; the conditions of the spray drying include: the air inlet temperature is 170-180 ℃, and the air outlet temperature is 90-105 ℃.
7. The preparation method according to claim 3, wherein the particle size of the obtained Salvia miltiorrhiza powder or Ganoderma lucidum powder is 10-16 mesh after the Salvia miltiorrhiza and Ganoderma lucidum are pulverized; the particle diameters of the pseudo-ginseng and the safflower are independent and are 80-100 meshes.
8. The use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for resisting oxidation and enhancing immunity.
9. Use of the Chinese medicinal composition of claim 1 or 2 for the preparation of a medicament for preventing thrombosis and/or improving cardiac function.
10. The use according to claim 8 or 9, wherein the medicament is in the form of tablets, powders, capsules, oral liquids, injections, sprays, aerosols, powders, lotions, liniments, ointments, emulsions, patches, eye drops, nasal drops, suppositories, pills, microsphere preparations or tinctures.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011222240.8A CN112336764A (en) | 2020-11-05 | 2020-11-05 | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011222240.8A CN112336764A (en) | 2020-11-05 | 2020-11-05 | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112336764A true CN112336764A (en) | 2021-02-09 |
Family
ID=74428775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011222240.8A Pending CN112336764A (en) | 2020-11-05 | 2020-11-05 | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112336764A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363391A (en) * | 2001-01-04 | 2002-08-14 | 李晔 | Garnoderma product and its preparing process |
| CN101085012A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing safflower for treating cardiovascular diseases and its preparation |
| CN105876781A (en) * | 2016-03-18 | 2016-08-24 | 蔡晓妹 | Preparation method of health-care food significantly lowering high blood lipids, high blood pressure and high blood sugar, and enhancing immunity |
-
2020
- 2020-11-05 CN CN202011222240.8A patent/CN112336764A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363391A (en) * | 2001-01-04 | 2002-08-14 | 李晔 | Garnoderma product and its preparing process |
| CN101085012A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing safflower for treating cardiovascular diseases and its preparation |
| CN105876781A (en) * | 2016-03-18 | 2016-08-24 | 蔡晓妹 | Preparation method of health-care food significantly lowering high blood lipids, high blood pressure and high blood sugar, and enhancing immunity |
Non-Patent Citations (4)
| Title |
|---|
| 姚海扬，等: "《中国滋补五保》", 31 October 2015, 山西科学技术出版社 * |
| 宋怀方，等: "复方丹参片对糖尿病人超氧化物歧化酶活力及血液流变学的影响", 《药学进展》 * |
| 王亚东，等: "三七和灵芝孢子粉提取混合物对小鼠免疫功能的影响", 《郑州大学学报：医学版》 * |
| 罗珊珊，等: "彝药参芪益心胶囊治疗冠心病的临床研究", 《光明中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230057438A (en) | Compositions of ginsenosides Rg3 and ginsenosides Rg5 and pharmaceutical uses thereof, including antitumor effects | |
| CN113577230A (en) | Composition for preventing and delaying occurrence and development of senile dementia and application thereof | |
| CN103355655A (en) | Composition with alimentary anemia improving function and preparation method of composition | |
| CN108014150A (en) | Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared | |
| CN1943707B (en) | A Chinese traditional medicinal composition for anti-aging and its preparation method | |
| WO2023125797A1 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
| CN105056128B (en) | A kind of Chinese medicine composition and preparation method and application for treating atrophic gastritis and intestines | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN112336764A (en) | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN107536016B (en) | A nutritional food for protecting heart and promoting liver health | |
| CN103845524B (en) | It is a kind of to treat the Chinese medicine composition and preparation method and purposes that kidney essence deficiency is demonstrate,proved after tumor radiotherapy, chemotherapy | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN114931600B (en) | Traditional Chinese medicine composition for preventing and treating altitude stress and preparation method thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN108201602A (en) | A kind of Chinese medicine composition for having effects that assist reducing blood lipid and/or protect blood vessel and preparation method thereof and product | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN107320528A (en) | A kind of Chinese medical extract and medicine for treating alpastic anemia | |
| CN107495364B (en) | Health food for delaying senility and preparation method thereof | |
| CN106727799A (en) | A kind of health-preserving health-care Chinese medicine composition and preparation method thereof | |
| CN105639636A (en) | Health care food with liver protection and blood sugar reduction functions and making method thereof | |
| CN105250919B (en) | It is a kind of for preventing and/or the Chinese medicine composition for treating liver disease and preparation method thereof | |
| CN115836702A (en) | Composite plant peptide tablet candy with immunity improving function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210209 |
|
| RJ01 | Rejection of invention patent application after publication |